Rapport Therapeutics, Inc. (RAPP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$43.89-4.77%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Rapport is advancing RAP-219 to Phase 3 trials by Q2 2026. Topline trial results are expected in Q4 2026. The company focuses on neurodegenerative diseases, a big unmet need. Analysts raised price targets, showing some confidence.
Rapport is still loss-making with negative EPS expected through 2027. Litigation and competitor data pose risks. The company has no current revenue and uncertain trial outcomes.
The price is about 29% below our fair value near $56. The market expects negative growth and losses to continue. Our view aligns with Street targets but sees risk in trial progress.
Breaks if: EPS loss worsens beyond -4.4 in FY27
Breaks if: Phase 3 trials not initiated by end of Q2 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis is cautious due to recent earnings misses and low confidence in future performance.
The market appears to have low expectations for RAPP, given its loss-making status and recent weak financial results. However, there is a low fragility tier, suggesting that the stock is not overly sensitive to negative news at this time.
Fundamentals may remain weak in the near term, especially if the company cuts guidance or if economic conditions worsen. Management is focused on advancing clinical trials, which could provide some positive momentum if successful.
The thesis hinges on the outcomes of ongoing clinical trials and the performance of sector peers. Positive developments in the healthcare sector could lift RAPP, while continued earnings misses or economic downturns may lead to further challenges.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company aims to achieve topline results for its RAP-219 Phase 2 bipolar mania trial in 2026-Q4. However, it recently missed earnings expectations, which raises concerns.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Accelerate the initiation of Phase 3 trials for RAP-219 in focal onset seizures to Q2 2026.
Breaks if: No topline results by end of Q4 2026
In the next 1 to 3 years, RAPP's performance will depend heavily on trial results and broader sector trends. Not investment advice.